FTC To Drop Antitrust Suit Over Lundbeck Heart Defect Drug

By Melissa Lipman

Law360, New York (January 23, 2012, 5:36 PM ET) -- The Federal Trade Commission has decided not to ask the U.S. Supreme Court to revive its suit accusing Lundbeck Inc. of illegally cornering the market on drugs used to treat heart defects in premature babies, the agency said Friday.

The decision will leave in place the Eighth Circuit's August ruling affirming the dismissal of the case — brought jointly with the state of Minnesota — after the court concluded that the FTC had failed to identify a relevant market. The panel ruled that the two drugs...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles